---
title: "CytoSorbents Advances FDA Pathway for DrugSorb Programs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290853071.md"
description: "CytoSorbents (CTSO) announced it has scheduled two FDA pre-submission meetings for August 2026 to discuss its ticagrelor and direct oral anticoagulant DrugSorb programs. This step aims to advance U.S. regulatory approvals for blood purification technologies, including DrugSorb-ATR for cardiac surgery patients. The company currently holds a 'Hold' rating with a $0.75 price target, while AI analysis cites neutral sentiment due to weak financials despite improved cost controls."
datetime: "2026-06-25T13:48:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290853071.md)
  - [en](https://longbridge.com/en/news/290853071.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290853071.md)
---

# CytoSorbents Advances FDA Pathway for DrugSorb Programs

An update from Cytosorbents ( (CTSO) ) is now available.

On June 24, 2026, CytoSorbents presented at the 2026 Life Sciences Forum and disclosed that it has scheduled two FDA pre-submission meetings in August 2026 to discuss its ticagrelor and direct oral anticoagulant programs, a key step toward potential U.S. regulatory approvals. The update underscores the company’s push to expand its blood purification technology into the U.S. market, build on its existing CE-marked indications, and advance DrugSorb-ATR for reducing perioperative bleeding risk in cardiac surgery patients on blood thinners, developments that could materially influence its regulatory trajectory and commercial footprint in acute care.

The most recent analyst rating on (CTSO) stock is a Hold  
with a $0.75 price target.  
To see the full list of analyst forecasts on Cytosorbents stock,  
see the CTSO Stock Forecast page.

**Spark’s Take on CTSO Stock**

According to Spark, TipRanks’ AI Analyst, CTSO is a Neutral.

The score is held down mainly by weak financial fundamentals (ongoing losses, cash burn, and high leverage) and bearish technicals (price below key moving averages with negative MACD). Earnings-call updates provide some offset through improved cost control, better adjusted profitability, and a stated path toward cash-flow breakeven, but near-term liquidity and regulatory timing risks remain material.

To see Spark’s full report on CTSO stock,  
click here.

**More about Cytosorbents**

CytoSorbents Corporation is a U.S.-based medical device company listed on Nasdaq that specializes in acute care blood purification using proprietary, biocompatible porous polymer bead technology. Its flagship product, CytoSorb, is CE-marked in the European Union for cytokine, bilirubin, myoglobin, and certain blood thinner removal, is distributed in more than 70 countries with over 300,000 treatments, generated $37.1 million in sales in 2025 with 71% gross margins, and is supported by strategic partnerships and significant U.S. government funding, while it pursues FDA and Health Canada approvals for its DrugSorb-ATR platform.

**Average Trading Volume:** 156,557

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $26.96M

Find detailed analytics on CTSO stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [CTSO.US](https://longbridge.com/en/quote/CTSO.US.md)

## Related News & Research

- [CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update | CTSO Stock News](https://longbridge.com/en/news/286308377.md)
- [Is Cytokinetics (CYTK) Cheap Or Has Its Cardiac Growth Story Already Been Priced In?](https://longbridge.com/en/news/294025789.md)
- [James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition](https://longbridge.com/en/news/294085325.md)
- [Brandenburg Kapital portfolio firm 4TEEN4 wins FDA fast-track status for cardiogenic shock drug Invobenitug](https://longbridge.com/en/news/294323930.md)
- [Incyte expects Opzelura to cross $1B in 2026](https://longbridge.com/en/news/294223769.md)